Document is current
Any future updates will be listed below
-
Authors
Ravlo, Erlend
Ianevski, Aleksandr
Schjølberg, Jørn-Ove
Solvang, Vanessa
Dumaru, Rabina
Lysvand, Hilde
Hankinson, Jacqueline
Vähä-Koskela, Markus
Vainionpää, Sanna
Varhe, Anni
Seppänen, Hanna
Smura, Teemu
Wang, Xin
Wang, Yining
Li, Pengfei
Pan, Qiuwei
Dahl-Jorgensen, Knut
Krogvold, Lars
Kamyshnyi, Oleksandr
Nilsen, Hans-Johnny Schjelderup
Haugen, Inger Johanne
Høyer, Erling
Afset, Jan Egil
Oksenych, Valentyn
Galabov, Angel S.
Stoyanova, Adelina
Lam, Vivian
van Loon, Barbara
Lulla, Valeria
Bjørås, Magnar
Kainov, Denis E. https://orcid.org/0000-0001-7716-6955
-
Funding
Funding for this research was provided by:
NTNU Norwegian University of Science and Technology
- License Information
-
More Information
Article History
Received: 25 July 2024
Revised: 18 November 2024
Accepted: 5 January 2025
First Online: 23 January 2025
Declarations
:
: The study involved commercially available human cell lines, WT virus strains, which we isolated from patient samples or obtained via collaborations. All experiments with viruses were performed in BSL2 laboratories in compliance with the guidelines of the national authorities, and under appropriate ethical and safety approvals. All experiments conducted with pancreatic cancer organoids have been approved by the Helsinki University Hospital ethical board, HUS/74/2023, HUS/23/2024. The Medical Ethical Committee of the Erasmus MC Rotterdam granted permission for study on lung organoids (METC 2012 − 512).
: The authors have no relevant financial or non-financial interests to disclose.
